Arvinas Inc. (ARVN) News, Price and Chart - FAWS

Your browser has either disabled or does not support javascript. Javascript is required for full website experience.

Thu March 18th, 2021

- 19:52
  AnalysisArvina (ARVN) Investor Presentation - SlideshowSeeking Alpha

Wed March 10th, 2021

- 18:37
  AnalysisKymera Therapeutics: Selective Protein Degradation Second Mover To WatchSeeking Alpha

Mon March 1st, 2021

- 13:15
  AnalysisArvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue EstimatesZacks

Thu February 25th, 2021

- 18:01
  AnalysisThe Brave New Genomic WorldSeeking Alpha

Wed February 10th, 2021

- 20:04
  ^{0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9}
  AnalysisHealthcare Is Ready To Lead In 2021Seeking Alpha

Tue February 2nd, 2021

- 01:56
  ^{0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9}
  AnalysisESSA Pharma: Update Including Clinical Collaboration Agreement With JanssenSeeking Alpha

Mon January 11th, 2021

- 13:00
  AnalysisBiotech Bonanza: 2021 Outlook In A Post-Pandemic YearSeeking Alpha

Sat January 2nd, 2021

- 20:00
  ^{0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9}
  AnalysisArvinas: Leading In Cutting Edge Protein Degrader DevelopmentSeeking Alpha

Sun December 27th, 2020

- 10:00
  AnalysisC4 Therapeutics: Preclinical Stage Protein Degrader Developer With A Differentiated ApproachSeeking Alpha

Tue December 15th, 2020

- 14:17
  ^{0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9}
  AnalysisArvinas (ARVN) Up on Promising Interim Data on Cancer CandidatesZacks
- 12:34
  RatingArvinas upgraded to outperform from perform at OppenheimerMarketWatch

Mon November 16th, 2020

- 17:42
  IPOAnalysisIPO Update: Olema Pharmaceuticals Finalizes IPO PlanSeeking Alpha

Mon November 2nd, 2020

- 19:59
  ^{0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9}
  IPOAnalysisOlema Pharmaceuticals Starts U.S. IPO PlanSeeking Alpha

Wed August 19th, 2020

- 15:48
  ^{0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9}
  AnalysisESSA's Novel Prostate Cancer Treatment In Clinical Trial: Pfizer Is New Lead InvestorSeeking Alpha

Mon August 17th, 2020

- 23:02
  ^{0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9}
  IPOAnalysisIPO Update: Kymera Therapeutics Readies $125 Million IPOSeeking Alpha

Tue August 4th, 2020

- 13:05
  ^{0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9}
  AnalysisArvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue EstimatesZacks

Mon July 27th, 2020

- 16:31
  EarningsAnalysisEarnings Preview: Arvinas, Inc. (ARVN) Q2 Earnings Expected to DeclineZacks

Tue July 21st, 2020

- 19:55
  IPOAnalysisIPO Update: Nurix Therapeutics Prepares IPO TermsSeeking Alpha

Wed July 8th, 2020

- 19:01
  IPOAnalysisNurix Therapeutics Files For U.S. IPOSeeking Alpha

Fri June 12th, 2020

- 20:42
  AnalysisArvinas (ARVN) Investor Presentation - SlideshowSeeking Alpha

Fri June 5th, 2020

- 16:00
  RatingAnalysisArvinas, Inc. (ARVN) Upgraded to Buy: Here's WhyZacks

Fri May 22nd, 2020

- 14:22
  Screening For The Best Growth StocksSeeking Alpha

SPY$395.63-3.2%

QQQ$315.85-5.7%

DOW$64.141.5%

CCF$115.74-1.5%

NVDA$513.35-10%

SPY$395.63-3.2%

QQQ$315.85-5.7%

DOW$64.141.5%

CCF$115.74-1.5%

NVDA$513.35-10%

About Developer Contact